Japanese artificial intelligence system diagnoses colorectal cancer in 0.3 seconds

Share This Post

Japanese researchers have developed an artificial intelligence system that extends an endoscope with a magnification of 500 times into the patient ‘s intestine. The artificial intelligence system can identify whether there is malignant change in the large intestine polyp in the endoscope within 0.3 seconds, according to real-time judgment results The doctor can decide whether to operate in real time.

Compared with the past, it takes a week to make a diagnosis, and now the system can immediately determine whether to remove it, which greatly improves the efficiency of diagnosis and treatment. During the development of this system, more than 60,000 tumor cell pictures were used to build a database. These pictures came from more than 3,000 patients with colorectal cancer diagnosed in 5 hospitals in Japan. By analyzing and deep learning the tumor images in the image database, the system has learned the automatic recognition function of cancer. Not only improve the diagnosis efficiency, but also improve the accuracy.

In Japan, colorectal cancer is the second most malignant tumor after death from lung cancer. Early detection is the key to improving the level of treatment. This artificial intelligence achievement in Japan can detect the presence of cancer in large intestine polyps in less than a second. At present, this artificial intelligence colorectal cancer diagnostic system has been clinically tested in 6 hospitals in Japan, and is expected to obtain the license from the relevant Japanese pharmaceutical regulatory authorities in 2018. 

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

After amazing growth of CAR T-Cell therapy what's next
CAR T-Cell therapy

After amazing growth of CAR T-Cell therapy: what’s next?

CAR T-cell therapy has rapidly transformed cancer treatment by reprogramming a patient’s T-cells to attack cancer cells, demonstrating remarkable success in hematologic cancers. Advances in genetic engineering, regulatory support, and investment are driving further expansion. Researchers are now tackling the challenges of applying this therapy to solid tumors, aiming to enhance efficacy and accessibility, marking a new era in personalized cancer therapy and immunotherapy.

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate, a groundbreaking treatment, has recently received approval from the US Food and Drug Administration (FDA) for pediatric patients, marking a significant milestone in pediatric oncology. This approval represents a beacon of hope for children battling neuroendocrine tumors (NETs), a rare but challenging form of cancer that often proves resistant to conventional therapies.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy